Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Hong-Juan Yao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5031364662. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 4

  1. ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. Co-author DOI 10.1016/j.mcp.2025.102030↗
  2. Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. Co-author DOI 10.1080/21691401.2023.2264358↗
  3. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗
  4. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic… Co-author DOI 10.1002/cam4.1974↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liang Li · 4 shared papers, 2019–2025 · strength 0.59
  2. Yuchen Shi · 3 shared papers, 2022–2025 · strength 0.49
  3. Hebing Chen · 3 shared papers, 2022–2025 · strength 0.49
  4. Xiaofei Zhou · 2 shared papers, 2022–2023 · strength 0.29
  5. Rong‐Guang Shao · 2 shared papers, 2019–2022 · strength 0.23
  6. Rui Cao · 2 shared papers, 2019–2022 · strength 0.23
  7. Qifeng Xiao · 1 shared paper, 2025 · strength 0.20
  8. Chenyu Yuan · 1 shared paper, 2025 · strength 0.20
  9. Xiaohong Liu · 1 shared paper, 2025 · strength 0.20
  10. Xiaohong Liu · 1 shared paper, 2023 · strength 0.16
  11. Yi Li · 1 shared paper, 2022 · strength 0.13
  12. Li Zhang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.